Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylnaltrexone bromide - Bausch Health Companies/Progenics Pharmaceuticals

Drug Profile

Methylnaltrexone bromide - Bausch Health Companies/Progenics Pharmaceuticals

Alternative Names: Methyl-naltrexone hydrobromide; Methylnaltrexonium; MNTX; MNTX 302; MOA-728; MRZ 2663BR; MRZ-2663; N-methylnaltrexone bromide; Naltrexone MB; Naltrexone methobromide; Naltrexone methylbromide; Naltrexonium methiodide; ONO-3849; Quaternary ammonium naltrexone; Relistor; Relistor Oral

Latest Information Update: 19 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Chicago
  • Developer Glycyx Pharma Ventures; Ono Pharmaceutical; Progenics Pharmaceuticals; Salix Pharmaceuticals
  • Class Morphine derivatives; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Constipation

Highest Development Phases

  • Marketed Constipation
  • Research Pancreatic cancer
  • Discontinued Postoperative ileus; Urination disorders

Most Recent Events

  • 05 Nov 2019 Bausch Health Americas plans a phase III extension study in Pancreatic cancer (Late-stage disease) in February 2020 (PO)(NCT04151719)
  • 11 Sep 2019 Bausch Health Americas plans a phase II/III trial in Pancreatic cancer (Late-stage disease, Inoperable/Unresectable) (SAL-REL2042; NCT04083651)
  • 17 Jul 2019 US District Court of New Jersey upholds the validity and determined Actavis' infringement of patent protecting methylnaltrexone bromide tablets
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top